PSTI - Pluristem Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9800
+0.0010 (+0.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9790
Open0.9750
Bid0.0000 x 2200
Ask0.0000 x 800
Day's Range0.9601 - 0.9800
52 Week Range0.6600 - 1.5200
Volume307,891
Avg. Volume246,406
Market Cap114.52M
Beta (3Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.2480
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.25
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company has fully enrolled the second cohort of six patients in its ongoing Phase I clinical study evaluating PLX-R18 for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT), and has received Data and Safety Monitoring Board (DSMB) approval to continue to the final cohort of the study. “We are highly encouraged by the findings from the first two cohorts in this study, and we are pleased to receive DSMB approval to continue with the study as planned, as we look to efficiently advance PLX-R18 through clinical development,” commented Zami Aberman, Chairman and Co-Chief Executive Officer of Pluristem.

  • Is Pluristem Therapeutics Inc.’s (NASDAQ:PSTI) Balance Sheet A Threat To Its Future?
    Simply Wall St.14 days ago

    Is Pluristem Therapeutics Inc.’s (NASDAQ:PSTI) Balance Sheet A Threat To Its Future?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Pluristem Therapeutics Inc. (NASDAQ:PSTI), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...

  • GlobeNewswire29 days ago

    Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced a collaboration between the company and NASA’s Ames Research Center to evaluate the potential of Pluristem’s PLX cell therapies in preventing and treating medical conditions caused during space missions. Dr. Ruth Globus of NASA’s Ames Research Center, in California’s Silicon Valley, has been awarded a 2019 NASA Ames Research Innovation Award (ARIA) for the collaboration with Pluristem.

  • Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    Pluristem Therapeutics Inc. (PSTI) has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswirelast month

    RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics

    Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, today announced that the large-scale research initiative, RESTORE, of which Pluristem is a member, is nominated to be one of two finalists competing to be awarded up to €1 billion over the next 10 years by the EC for the development and advancement of transformative therapeutics. As a member of the RESTORE consortium, if RESTORE wins the award, Pluristem could receive a portion of the award, the amount of which is not yet determinable.

  • Associated Presslast month

    Pluristem: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Haifa, Israel-based company said it had a loss of 7 cents. The biotechnology company posted revenue of $50,000 in the period. In the final minutes of trading on Wednesday, the ...

  • Read This Before Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares
    Simply Wall St.2 months ago

    Read This Before Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...

  • GlobeNewswire2 months ago

    Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported the receipt of a joint grant awarded by the Israeli Ministry of Defense and the Israel Innovation Authority for the development of the company’s PLX cells for the treatment of burn injuries. This project entails collaboration between the Company, the Israeli Defense Forces (IDF) medical corps and professionals who specialize in burn injuries from Israeli hospitals.

  • GlobeNewswire2 months ago

    Pluristem Therapeutics Reports Successful Case Study in Treatment of Buerger’s Disease Patient

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative-medicine company developing novel placenta-based cell therapy products, today reported a successful one-year follow up of a compassionate use treatment in a Buerger’s disease patient treated with Pluristem’s PLX-PAD. The thirty-six years old patient, who was diagnosed with Buerger’s disease approximately four years ago, displayed painful, non-healing ulcers on his foot.

  • GlobeNewswire3 months ago

    Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced it has concluded a positive meeting with the U.S. Food and Drug Administration (FDA) regarding the ongoing development of PLX-R18 for the treatment of Acute Radiation Syndrome (ARS). The FDA provided Pluristem with feedback on the progress and data collected on PLX-R18 to date and gave guidance towards advancing the development of PLX-R18 with respect to the treatment of ARS.

  • GlobeNewswire3 months ago

    Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD)

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today provided a recap of the Key Opinion Leader (KOL) breakfast meeting on peripheral artery disease (PAD) that the Company hosted on Friday, December 14 in New York. The meeting focused on the current treatment landscape, unmet medical need, economic impact and potential market opportunities for treating patients with PAD, a serious but common circulatory problem characterize by a blockage of the arteries and reduced blood flow to the limbs.

  • What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc (NASDAQ:PSTI)?
    Simply Wall St.4 months ago

    What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc (NASDAQ:PSTI)?

    The big shareholder groups in Pluristem Therapeutics Inc (NASDAQ:PSTI) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...

  • GlobeNewswire4 months ago

    Report: Exploring Fundamental Drivers Behind Pluristem Therapeutics, RXi Pharmaceuticals, Saga Communications, Global Self Storage, Sequential Brands Group, and Finjan — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented additional data from its Phase II clinical study evaluating PLX-PAD for the treatment of Intermittent Claudication (IC) at the 2018 American Heart Association Scientific Sessions in Chicago. The data were presented by Prof. Norbert Weiss, MD, Director of the Vascular Center at the Technical University of Dresden, Germany, and the lead European Principal Investigator for the Phase II IC study.

  • Associated Press4 months ago

    Pluristem: Fiscal 1Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 8 cents per share. The biotechnology company posted revenue of $4,000 in the period. The company's shares closed at $1.18. A year ago, they were trading ...

  • GlobeNewswire4 months ago

    Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fiscal first quarter 2019 ended September 30, 2018 and provided a corporate update. “We were very pleased to announce this quarter on FDA approval of an expanded access program that will provide critical limb ischemia patients who are not suitable for enrollment in our Phase III trial with access to PLX-PAD while the trial is ongoing,” said Yaky Yanay, Co-Chief Executive Officer and President of Pluristem. “During the fiscal first quarter and subsequent period, we continued to make progress advancing our pipeline of novel placenta-based cell therapy products in multiple indications.” Mr. Yanay continued, "We are making good progress in enrolling patients in both ongoing Phase III clinical trials of PLX-PAD in critical limb ischemia (CLI) and the treatment of muscle injury following hip fracture.